Introduction
No consensus was reached regarding defining what constitutes pharmaceutical innovation 1 . In fact, neither the attributes of an innovative product nor the criteria to be considered when assessing its innovation have been clearly established 2 . In general, new medicines are commonly believed to be therapeutically innovative and offer better health outcomes than older drugs 3, 4, 5 , although that is not confirmed in the clinical practice 6 . It is currently accepted that a new compound must have a clinically relevant advantage when compared head-to-head with existing established therapies to be considered innovative 7, 8 ; such as showing better population indicators for morbidity, mortality and quality of life. This notion of therapeutic advance can be useful to recognize and reward medicine manufacturers that develop products with a high therapeutic value and, therefore, to encourage and sustain the innovation 2,9 that meets patients' needs 10, 11 .
The list of advantages of innovative drugs when compared with available therapeutic options are 2 : greater efficacy/effectiveness and safety; improved patients' quality of life and satisfaction; reduction in treatment costs; better therapeutic outcomes in patient subgroups; or enabling treatment of otherwise unmet medical needs. The decision to introduce the new drug into the clinical practice must consider these aspects as well as users' and providers' interests 2, 12 . Several methods have been proposed to probe and define the added therapeutic value of new medicines 7, 13, 14, 15, 16, 17 . Generally, therapeutic advance is identified when a the superiority of a drug is shown in methodologically robust studies, using active comparators and hard clinically relevant outcomes 16, 18 .
Added therapeutic value assessors generally agree that therapeutic advance is rare, despite the alleged increase in research and development costs 16 . A recent report by Public Citizen in the US showed despite very high profits of more than 100 billion USD per year, the 20 largest pharmaceutical corporations only reported spending half that amount on research and development (R&D) for new medicines 19 . Researchers have called on governments to define policies to align R&D and real health needs 10, 11 .
The assessment of added therapeutic value can guide clinical decisions by healthcare professionals, thus benefiting patients 2, 15 ; and it drives more effective and efficient decisions in health systems. This is particularly important in poorer settings in which drug selection enables the allocation of resources -and therefore access -of those medicines that benefit the population the most 20 .
Difficulties in accessing health services and medicines remain a global social problem of great concern 20 . Brazil is no exception, even though it was the 8 th largest pharmaceutical market in the world during 2016, with sales volumes amounting to approximately 28 billion USD 21 .
A policy to improve the access to medicines through price-control measures 22 , based on incentive mechanisms to increase the sector's offer and competitiveness, was established in Brazil in 2004. This was the first Brazilian policy enshrining systematic health technology assessment (HTA) as a component of price-setting procedures and being applied to all new drugs approved by the Brazilian health authority -Brazilian Health Regulatory Agency (Anvisa). The maximum price to be borne depends on the added therapeutic value of the drug 22, 23 .
A cross-sectional study 24 of new pharmaceutical products registered in Brazil between 1999 and 2004 concluded that many of the medicines approved were me-too drugs driven by market demands. Another descriptive study analyzed new medicines entering the Brazilian market between 2000 and 2004 and reported that only one third were innovative products and none was indicated to treat infectious diseases prevalent in developing countries 25 .
Bearing in mind the need to improve the access to and the rational use of medicines, our study aimed to assess the added therapeutic value of all new medicines registered in Brazil since the implementation of the HTA policy and to investigate their alignment with national public health needs.
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Methods

Study design
We conducted a comparative descriptive analysis of therapeutic value assessments for new medicines receiving marketing authorization in Brazil, from January 1 st 2004 to December 31 st 2016, and examined their alignment with local therapeutic needs.
Data collection
New medicines approved by Anvisa -from January 1 st 2004 to December 31 st 2016 -were identified under the codes 175, 1,458, 10,464 or 1,528, which represented respectively: entry for a new medicine, electronic entry for a new medicine, entry for a new biological product. Even though vaccines are biological products, they were excluded from our study as they are identified as non-innovative by the Brazilian criteria 22, 26 .
The following general data were collected for each medicine: name and country of origin of manufacturer; composition; Anatomical Therapeutic Chemical Classification (ATC, 5 th level) 27 ; date of the first authorization in Brazil; and indications approved.
Assessing the added therapeutic value of new medicines
The Brazilian Chamber of Drug Market Regulation (CMED) is an interministerial Brazilian body responsible for setting the prices of new medicines. It evaluates and classifies products into one of the six categories divided into two groups: new molecules (categories I and II) and new formulations (categories III, IV, V and VI). A new medicine is considered innovative (category I) when it contains a molecule (active ingredient) under national patent and offers a proven treatment gain when compared with available treatment options for that same indication. That treatment gain is translated into greater efficacy, or similar efficacy with significant reduction in adverse effects, or similar efficacy with a significant reduction in the overall treatment costs. A medicine is classified as category II i.e. as non-innovative if it has a new molecule (active ingredient) without patent in Brazil or if it does not bring any treatment gain 22, 26 .
The independent drug bulletin Prescrire evaluates new drugs or new indications approved in France, according to their efficacy, safety and convenience. The Prescrire bulletin and its English edition Prescrire International are fully financed by subscriptions and do not accept advertising or external sponsorship. Prescrire classifies new drugs or new indications into added therapeutic value categories as follows 28 : (a) Bravo: the product represents a major therapeutic advance in an area in which previously no treatment was available; (b) A real advance: the product is an important therapeutic innovation but has certain limitations; (c) Offers an advantage: the product has some value but does not fundamentally change the current therapeutic practice; (d) Possibly helpful: the product has minimal additional value and should not change prescribing habits except in rare circumstances; (e) Nothing new: the product may be a new substance but it is superfluous because it does not add to the clinical possibilities offered by previous products available; (f) Not acceptable: product without evident benefit but with potential or real disadvantages; (g) Judgement reserved: the editors postpone their rating until better data and a more thorough evaluation of the drug are available.
New medicines were dichotomously classified, as to their added therapeutic value, when compared with available therapies for the same indication, into "therapeutic innovation" or "no therapeutic innovation". To do so, we used the assessments provided by the CMED and Prescrire. The first rating -CMED -stems from an official body of the Brazilian government responsible for implementing the national drug pricing policy and is the only systematic assessment of drug innovativeness available in Brazil based on clear criteria. The second rating is conducted by Prescrire, which is an Cad. Saúde Pública 2019; 35(5):e00070018 independent and globally acknowledged drug bulletin that has published systematic drug reviews for more than three decades. Both entities have assessed most of the medicines included in our sample. The comparison of both ratings aims to contrast a governmental and an independent assessment. In a similar analysis in Canada, the Prescrire criteria were divided into two broad categories 29 . We have also applied this categorization, considering all the medicines rated within the first three Prescrire's categories (bravo, real advance, offers an advantage) as "therapeutic innovation" and those belonging to the remaining categories (possibly useful, nothing new and not acceptable) as "no therapeutic innovation". Medicines that Prescrire judged to have insufficient evidence to rate for therapeutic advantage are included under the category judgment reserved 29 .
Adoption of drugs in national listings of the Brazilian Unified National Health System (SUS)
In Brazil, the National Committee for Technology Incorporation (CONITEC), created in 2011, is the resposible for governmental health technology assessment decisions 30 . CONITEC's reviews are based on scientific evidence, considering aspects such as efficacy, accuracy, effectiveness and safety, as well as the comparative economic evaluation of the benefits and costs of new technologies versus existing ones. The data from the Committee were retrieved from its public website to assess whether new medicines authorized by Anvisa had been adopted or excluded from the national coverage lists as well as from clinical guidelines.
Alignment with national health needs
All new drugs approved during our study period were classified by the ATC code and their approved indications were compared with the conditions contributing the most to the Brazilian disease burden, as measured in disability-adjusted life years (DALYs) 31 . A conservative approach was adopted when attributing indications to the various conditions, i.e. only allocating approved indications and the ATC code into specific conditions that matched that indication.
Data analysis
Descriptive statistics are reported with all variables presented as absolute numbers and proportions. The kappa index 32 was calculated to determine the level of agreement between CMED and the grouped Prescrire therapeutic value ratings in our study sample. We used Epi Info (https://www.cdc. gov/epiinfo/index.html) version 7.1.4.0 and IBM SPSS (https://www.ibm.com/) version 24 for data analysis.
Results
From January 1 st 2004 to December 31 st 2016, 268 new pharmaceutical products were approved by Anvisa. From these, 253 were considered for analysis, after excluding 15 vaccines (Figure 1 ). Antineoplastics (L01: n = 44; 17.4%), immunosuppressants (L04: n = 18; 7.1%), systemic antivirals ( J05: n = 17; 6.7%) and antidiabetics (A10: n = 16; 6.3%) were the most frequent therapeutic classes.
The therapeutic value of 248 of these medicines was evaluated by at least one of the two institutions, and 183 by both (Figure 1 ). Among the drugs assessed by Prescrire, 16 out of 195 (8.2%) were considered therapeutic innovations, as per the grouped Prescrire criteria. Thirty-three out of 236 drugs assessed by Brazilian CMED were rated as therapeutic innovations (Table 1) . Five drugs -laronidase, nivolumab, pasireotide, sofosbuvir and sunitinib -were considered by both evaluators to be therapeutic innovations. As shown in Table 2 , the therapeutic classes with the most innovative drugs were: antineoplastic agents (n = 19); systemic antivirals (n = 7) and immunosupressants (n = 3). Eleven (4.3%) drugs were considered innovative by Prescrire but not by the Brazilian Chamber, whereas another 24 (9.5%) drugs were considered innovative by the CMED and non-innovative by Prescrire. Overall, the level of agreement between both ratings was weak [kappa = 0.123 (95%CI: 0.014; 0.260; p = 0.077)]. Forty-four (17.4%) out of 253 drugs in our sample were rated as therapeutic innovations by at least one of the criteria. From these, seven were adopted in the SUS coverage listings, which means that they are to be made freely available to Brazilian patients (Table 3) (Supplementary Material, Table  S1 : http://cadernos.ensp.fiocruz.br/site/public_site/arquivo/suppl-e00070018_6597.pdf). None of these drugs was included in the basic pharmaceutical care package nor aimed to treat a neglected disease. Of the 29 drugs adopted by the SUS rated as "no therapeutic innovation", 8 were only assessed by one of the criteria (Supplementary Material, Table S2 : http://cadernos.ensp.fiocruz.br/site/public_site/arquivo/suppl-e00070018_6597.pdf). Table 4 shows the distribution of indications approved in relation to the burden of disease. Sixty-three (30.9%) out of 204 non-therapeutically innovative drugs and 9 (20.4%) out of the 44 therapeutically innovative drugs aimed to treat a condition within the top 15 contributors to the national disease burden.
Discussion
This study has shown that relatively few new medicines approved in Brazil from 2004 to 2016 were considered therapeutic innovations and adopted in national drug listings. Most (82%) were noninnovative medicines.
Despite their low added therapeutic value ratings, more than 11% of these non-innovative drugs were included in government-funded drug listings. One-third of all new drugs approved during the study period aimed to treat one of the 15 conditions contributing the most to the Brazilian disease burden.
These are worrying findings from a public health perspective. First, they suggest many medicines approved in Brazil over the last 13 years had low utility levels 4 . Second, they indicate a poor allocation of resources by allowing public money to be spent on new, often expensive, non-innovative drugs. Although this is not different from more industrialized settings 33 , it is problematic for Brazil, where limited resources are available to ensure public coverage 34 . Finally, most new drugs entering the All other therapeutic products (V03) 2 50
Other hematological agents (B06) 2 100
Agents acting on the renin-angiotensin system (C09) 1 50
Antibacterials for systemic use (J01) 1 20 Antihypertensives (C02) 1 25
Antithrombotic agents (B01) 1 9
Endocrine therapy (L02) 1 33
Lipid modifying agents (C10) 1 20
Other alimentary tract and metabolism products (A16) 1 10
Other nervous system drugs (N07) 1 25 Pituitary and hypothalamic hormones and analogues (H01) 1 50
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Our results corroborate those of previous studies in which no more than 10% of newly approved drugs were considered therapeutic innovations 4, 6, 14, 24, 29 .
One could presume that the partial overlap between the indications approved and the national disease burden confirms that the available therapeutic arsenal is sufficient to treat the conditions contributing the most to DALYs. Yet, this mismatch shows a focus on new drug approvals for specific indications, such as oncology. This might be explained by the fact that market pressures do not necessarily mirror public health needs, especially for health conditions that mainly occur in low to medium income countries. Notwithstanding the importance medicines have in society as a treatment modality and their contribution to health care costs, the production of medicines is the domain of a few large multinational companies, which opt to focus on specific market niches and chronic conditions 36 . Four out of the five medicines considered therapeutically innovative by both CMED and the grouped Prescrire criteria have orphan drug product denomination either in the Europe or in the USA. Within our sample, antineoplastics, immunosupressants, systemic antivirals and antidiabetics were the most frequent therapeutic classes. In an analysis of clinical trials carried out in Brazil 37 , diabetes type 2, breast cancer and bronchial or lung cancer were among the conditions most frequently studied. While research in neglected diseases is a high priority for Brazil, it does not yield returns on investment for the pharmaceutical industry 37 . Nevertheless, there are two ongoing initiatives by multinational companies regarding neglected diseases in collaboration with the Institute of Drug Technology Farmanguinhos: a product development for a pediatric praziquantel formulation to treat schistosomiasis (now at phase 2); and a cooperative R&D agreement to develop a dengue virus vaccine (at preclinical stage) 38 .
Our study has shown that only 36 (14.2%) of the new medicines registered during these 13 years were listed for public coverage under the SUS, and that 21 out of the 36 medicines included in these listings were considered non-innovative by both CMED and Prescrire. Such a low number of therapeutic innovations stresses the importance of strengthening pharmacy and therapeutics committees 39, 40, 41 . While they have been established in many health facilities in Brazil, their roles are somewhat limited due to financial and human resources constraints 41 . Many new technologies receive poor health technology assessments. About 40% of all the HTA recommendations around the world are negative and so are those of CONITEC 42 . Suggestions were made to improve Anvisa procedures with a focus on added therapeutic value and systematic disclosure of assessment results. These measures would benefit medicine users, health professionals and managers 43 .
We found very weak agreement between CMED and Prescrire's evaluations of therapeutic innovativeness. This can be partly attributed to differences in the organizations, as well as their rationale and criteria. For instance, the Brazilian Chamber considers patent protection as a prerequisite for therapeutic innovation, whereas this is not the case for Prescrire. Intellectual property policies aim to ensure a financial return on investment by introducing a patent protection (and subsequent monopoly) to encourage technology development. Yet a drug that has a patent does not necessarily represent a therapeutic advance, as clinical outcomes are not a key criterion for patent attribution. Nonetheless, both criteria examine the available scientific evidence on the efficacy, safety and effectiveness of a drug. Our results mirror those of a Canadian study that compared drug assessments conducted by the Patented Medicine Prices Review Board (PMPRB) and Prescrire 29 . In addition, notwithstanding Prescrire's scientific standards, one could argue that its reviews are led by healthcare professionals living in another social, health and economic context than that of Brazil, and that, therefore, their ratings might not be transferable to other settings. Likewise, the political context in Brazil and changes in the government and at Anvisa might also have affected the CMED ratings. Moreover, assessing the therapeutic innovativeness of a drug compared with existing treatment options depends partly on other available treatments and can therefore vary by setting and over time. Nonetheless, the clarity and validity of the criteria adopted, their evidence-based approach and extensive peer review are all factors that minimize that likelihood.
Some caution is warranted when interpreting these assessments considering the absence of benchmark for the evaluation of the therapeutic value of new medicines. Many of the data used is Cad. Saúde Pública 2019; 35 (5):e00070018 available at the time of approval and is limited, as new evidence is likely to emerge at a later stage once the medicine has been marketed and used by a larger patient population 4 .
The CMED's under patent requirement as a prerequisite for therapeutic innovation is highly questionable. Although the existence of a patent presumes demonstrated progress over previous knowledge 16 , patents are frequently granted based on technical aspects unrelated to a drug's efficacy or its therapeutic benefits, and consequently play a limited role when ascertaining the quality of pharmaceutical innovation 16, 44 .
The data in this study were collected in parallel to and cross-referenced from different sources, most of which publicly available, thus contributing to the reliability of our findings. Additional studies would be needed to explore the divergence between therapeutic value assessment criteria and to promote greater harmonization and reproducibility.
This discussion on drug innovation cannot be separated from an analysis of the R&D trends both nationally and globally, as these reflect the interests and priorities of public and private research funders. Some authors have advocated that, to foster future innovation, the current criteria for drug approval should be changed to introduce clear demonstration of added therapeutic value as a requirement to obtain a marketing authorization 4, 45, 46 . A multi-stakeholder debate in Brazil put forward a dual role for the State: to stimulate and redirect research and development towards therapeutically innovative medicines treating unmet medical needs, and to reward value based on results 47 . While industry stakeholders in Brazil agree that innovation should bring therapeutic gains and real benefits for patients, they have called for early price-setting discussions, before investments are made in R&D, claiming that this would encourage national innovation 47 . Ultimately, clinical research priorities should be based on local epidemiological data, with value placed on studies that examine important health aspects and respond to current and future gaps in services, thus protecting systems from becoming reliant on a few multinational pharmaceutical companies that dominate the sector 48 . Undoubtedly, this approach would benefit Brazil, a major emerging economy that still faces many public health challenges while striving to provide universal health coverage.
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